Raymond James Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.5M Buy
777,268
+43,225
+6% +$592K ﹤0.01% 1885
2026
Q1
$9.12M Buy
734,043
+35,983
+5% +$483K ﹤0.01% 2099
2025
Q4
$8.8M Sell
698,060
-44,350
-6% -$507K ﹤0.01% 2082
2025
Q3
$7.43M Buy
742,410
+28,078
+4% +$252K ﹤0.01% 2159
2025
Q2
$5.78M Buy
714,332
+117,830
+20% +$888K ﹤0.01% 2273
2025
Q1
$5M Buy
596,502
+224,506
+60% +$1.87M ﹤0.01% 2326
2024
Q4
$2.95M Buy
+371,996
New +$3.12M ﹤0.01% 2688

Other funds holding AMRX

Raymond James Financial's AMRX Position: Q2 2026 in Review

Raymond James Financial increased its Amneal Pharmaceuticals (AMRX) stake by 5.9% in Q2 2026, buying an estimated $592K and bringing the position to 777,268 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

Raymond James Financial first reported a position in AMRX in Q4 2024 and has held it in 7 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Raymond James Financial held 777,268 shares of Amneal Pharmaceuticals worth $13.5M as of Q2 2026.
  • Raymond James Financial bought 43,225 Amneal Pharmaceuticals shares in Q2 2026, an estimated $592K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1885 holding.
  • Raymond James Financial first reported a position in Amneal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.